Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)

Reddit, Wingstop, and Generac led large-cap gains last week on strong Q2 results and upbeat guidance across multiple sectors.

Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum.

Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises.

Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics.

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.